Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 6—June 2004


SARS and Common Viral Infections

Janice K. Louie*†1Comments to Author , Jill K. Hacker*1, Jennifer Mark*, Shilpa S. Gavali*, Shigeo Yagi†, Alex Espinosa†, David P. Schnurr†, Cynthia K. Cossen†, Erin R. Isaacson†, Carol A. Glaser†, Marc Fischer‡, Arthur L. Reingold†, Duc J. Vugia*†, and for the Unexplained DeathsCritical Illnesses Working Group
Author affiliations: *California Emerging Infections Program, Berkeley, California, USA; †California Department of Health Services, Berkeley, California, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 1

Respiratory testing algorithma

Respiratory specimens Serologic testingb
Viral culture Acute-phase serum specimens: IgM
  Polymerase chain reaction Chlamydia spp.
  Influenza A Mycoplasma pneumoniae
  Influenza B Paired serum specimens: IgG
  Respiratory syncytial virus Chlamydia spp.
  Parainfluenza virus types 1–4 M. pneumoniae
  Human metapneumovirus Influenza A and B
  Coronavirus OC43 and 229E Respiratory syncytial virus
  Adenovirus Parainfluenza virus types 2–4
  Picornavirus Adenovirus

aIg, immunoglobulin; SARS-CoV, severe acute respiratory syndrome–associated coronavirus.
bAll serologic assays were in-house enzyme immunoassays (15), except for the Meridian IgM assay for M. pneumoniae (Meridian Bioscience, Inc., Cincinnati, OH) and enzyme-linked immunosorbent assay of the Centers for Disease Control and Prevention for SARS-CoV

Main Article

1Both authors contributed equally to this work.

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO